Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: exenatide


Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C)

March 16th 2020

Short-acting exenatide does not seem to have a future as a standard add-on treatment to insulin therapy in type 1 diabetes (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: exenatide, Type 1 Diabetes

Categories: Medication
Tags: exenatide, Type 1 Diabetes

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

August 7th 2018

Among patients with type 2 diabetes uncontrolled with metformin, exenatide QW plus dapagliflozin provided sustained improvements in glycemia, weight, and SBP over 52 weeks, with no unexpected safety findings (Diabetes Care)

Categories: Medication, News
Tags: dapagliflozin, exenatide, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, exenatide, Type 2 Diabetes

The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure

May 30th 2018

This review indicates that GLP-1 has no short-term effect on REE but may decrease DIT. The GLP-1RA exenatide and liraglutide had a neutral effect on REE, although it was not possible to rule out an increase in REE following prolonged treatment (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: exenatide, GLP1, liraglutide

Categories: Medication
Tags: exenatide, GLP1, liraglutide

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study

January 9th 2018

In this real-world data analysis, exenatide QW and exenatide BID were associated with similar glycemic control and greater weight reduction compared with basal insulin (Diabetes Therapy)

Categories: Medication, News
Tags: exenatide, glycaemic control, insulin, weight gain

Categories: Medication
Tags: exenatide, glycaemic control, insulin, weight gain

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

September 14th 2017

Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo (NEJM)

Categories: Medication, News
Tags: exenatide, EXSCEL, Type 2 Diabetes

Categories: Medication
Tags: exenatide, EXSCEL, Type 2 Diabetes

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

July 19th 2017

ExeOW is a well-tolerated and convenient option for long-term treatment of T2D allowing significant and persistent glycemic control with moderate weight loss and low risk of hypoglycemia unless associated with sulfonylureas (Advances in Therapy)

Categories: Medication, News
Tags: exenatide, Type 2 Diabetes

Categories: Medication
Tags: exenatide, Type 2 Diabetes

Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials

June 20th 2017

Exenatide QW improved glycemic outcomes and was well tolerated in patients with T2D for up to 156 weeks (Diabetes and Its Complications)

Categories: Medication, News
Tags: exenatide

Categories: Medication
Tags: exenatide

Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study

February 16th 2017

This study demonstrated that exenatide QWS-AI reduced HbA1c more than sitagliptin or placebo and was well tolerated (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: exenatide, metformin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: exenatide, metformin, sitagliptin, Type 2 Diabetes

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8)

November 29th 2016

Co-initiation of exenatide and dapagliflozin improved various glycaemic measures and cardiovascular risk factors in patients with type 2 diabetes inadequately controlled by metformin monotherapy. The dual treatment regimen was well tolerated, with the expected safety profile for this combination (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: dapagliflozin, exenatide, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, exenatide, Type 2 Diabetes

Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis

October 7th 2016

Although weight reduction is seen with all GLP-1RA’s, only the once weekly agents, exenatide LAR and dulaglutide, demonstrate significant HbA1c reductions when compared to basal insulins (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: Dulaglutide, exenatide, GLP-1RA, insulin, Type 2 Diabetes

Categories: Medication
Tags: Dulaglutide, exenatide, GLP-1RA, insulin, Type 2 Diabetes

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8)

September 16th 2016

Co-initiation of exenatide and dapagliflozin improved various glycaemic measures and cardiovascular risk factors in patients with type 2 diabetes inadequately controlled by metformin monotherapy. The dual treatment regimen was well tolerated, with the expected safety profile for this combination. Additional data from an ongoing study (eg, AWARD-10; NCT02597049) will further inform the use of these drug classes in combination (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: exenatide, Type 2 Diabetes

Categories: Medication
Tags: exenatide, Type 2 Diabetes

Exenatide Improves Beta-cell Function up to 3 Years of Treatment in Patients with Type 2 Diabetes: a Randomised Controlled Trial

August 1st 2016

Compared to insulin glargine, exenatide improved parameters of beta-cell function, especially insulin secretion at 8 mmol/L glucose and beta-cell glucose sensitivity, which was sustained during the three-year treatment period (European Journal of Endocrinology)

Categories: Medication, News
Tags: exenatide, Type 2 Diabetes

Categories: Medication
Tags: exenatide, Type 2 Diabetes

Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women

February 23rd 2016

These results suggest that the effect of exenatide on weight loss may be related with the suppression of serum ghrelin levels, which is an orexigenic peptide (Journal of Diabetes Research)

Categories: News, Obesity
Tags: exenatide

Categories: Obesity
Tags: exenatide

GLP-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in type 2 diabetes patients: a randomised trial

December 7th 2015

These findings suggest that potential adverse pancreatic effects of GLP-1 receptor agonists are not mediated by changes in exocrine pancreatic secretion (Diabetes, Obesity and Metabolism)

Categories: News, Pathology
Tags: exenatide, GLP-1 receptor agonists, Pancreas, Type 2 Diabetes

Categories: Pathology
Tags: exenatide, GLP-1 receptor agonists, Pancreas, Type 2 Diabetes

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

September 16th 2015

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD) (NewsMEDICAL)

Categories: Medication, News
Tags: exenatide

Categories: Medication
Tags: exenatide

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

February 18th 2015

Exenatide inhibited postprandial vascular endothelial dysfunction after the meal loading test, suggesting that exenatide has a multiphasic anti-atherogenic action involving not only glucose but also lipid metabolism (Cardiovascular Diabetology)

Categories: Medication, News
Tags: endothelial dysfunction, exenatide

Categories: Medication
Tags: endothelial dysfunction, exenatide

Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen

January 27th 2015

Each pre-filled pen contains 2 mg of exenatide. After reconstitution, each pen delivers a dose of 2 mg in 0.65 ml (EMC)

Categories: Medication, News
Tags: Bydureon, exenatide

Categories: Medication
Tags: Bydureon, exenatide

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study

January 26th 2015

Treatment with exenatide, with or without concomitant insulin was associated with reduced macrovascular risks compared to insulin; although inherent potential bias in epidemiological studies should be considered

Categories: Medication, News
Tags: exenatide, insulin, macrovascular

Categories: Medication
Tags: exenatide, insulin, macrovascular

Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus

January 20th 2015

Our study identified that baseline HbA1c acted as the sole predictor of exenatide response and that response may be determined after 3 months of exenatide administration (Journal of Diabetes Research)

Categories: Medication, News
Tags: exenatide, HbA1c, Type 2 Diabetes

Categories: Medication
Tags: exenatide, HbA1c, Type 2 Diabetes

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaSanofi DiabetesNovo NordiskNapp Diabetes

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Amgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone pregnancy retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership